Document Classification

Section Type: RESULTS

Text: At 12 weeks, tesaglitazar 0. 5 mg, 1. 0 mg, 2. 0 mg, and 3. 0 mg produced statistically significant reductions in FPG (-30. 3 mg/dL, -41. 1 mg/dL, -55. 0 mg/dL, -60. 9 mg/dL ; p < 0. 0001), triglycerides (-17. 2 %, -32. 9 %, -41. 0 %, -40. 9 % ; p < 0. 01), and apolipoprotein B (-15. 0 %, -15. 7 %, -21. 0 %, -22. 3 %, respectively ; p < 0. 0001).